Evolent Health, Inc. (EVH): who owns it and who trades it
As of Nov 16, 2026, EVH insiders reported 1 open-market sale worth $329K and 1 purchase worth $38.2K in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Daniel Joseph McCarthy (President), with $329K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Evolent Health
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns EVH
199 funds and institutions reported EVH shares worth $620M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 13.2%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 14.81M | 13.17% | $80.3M | +36% |
| Cadian Capital Management, LP | 10.81M | 9.61% | $58.6M | No change |
| Morgan Stanley | 8.97M | 7.97% | $48.6M | -1% |
| UBS Group AG | 6.25M | 5.55% | $33.8M | -23% |
| Rubicon Founders LLC | 5.82M | 5.17% | $31.5M | No change |
| Engaged Capital LLC | 5.56M | 4.95% | $30.2M | No change |
| D. E. Shaw & Co., Inc. | 5.11M | 4.54% | $27.7M | -6% |
| Vanguard Capital Management LLC | 4.79M | 4.26% | $26M | -2% |
| Marshall Wace, LLP | 3.41M | 3.03% | $18.5M | +335% |
| Nuveen, LLC | 3.13M | 2.78% | $17M | +1081% |
| Geode Capital Management, LLC | 2.90M | 2.58% | $15.7M | +11% |
| Rock Springs Capital Management LP | 2.50M | 2.22% | $13.6M | -7% |
| State Street Corp | 2.46M | 2.19% | $13.3M | -7% |
| Charles Schwab Investment Management Inc | 2.13M | 1.90% | $11.6M | +9% |
| Sixth Street Partners Management Company, L.P. | 2.13M | 1.90% | $11.6M | – |
| Goldman Sachs Group Inc | 1.75M | 1.55% | $9.5M | -22% |
| Rock Point Advisors, LLC | 1.72M | 1.53% | $9.3M | -4% |
| Jacobs Levy Equity Management, Inc | 1.60M | 1.42% | $8.7M | +163% |
| Kennedy Capital Management LLC | 1.57M | 1.39% | $8.5M | -2% |
| Vanguard Portfolio Management LLC | 1.35M | 1.20% | $7.3M | +45% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, EVH insiders reported $38.2K of open-market purchases and $329K of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 26, 2026 | Daniel Joseph McCarthy | President | Sale plan | 65,892 | $5.00 | $329K | Form 4 |
| Nov 18, 2025 | Brendan B Springstubb | Director | Purchase | 10,000 | $3.82 | $38.2K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Daniel Joseph McCarthy | PRESIDENT | – | $329K | Aug 26, 2026 |
| Brendan B Springstubb | Director | $38.2K | – | Nov 18, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
EVH short interest
Moderate short interest. 9.4% of EVH shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 29%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 10.61M EVH shares were sold short, 9.4% of the shares outstanding, down 10.9% from the report before. At the average daily volume of 1.52M shares, buying them all back would take about 7.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 10.61M | 9.38% | -11% | 1.52M | 7.0 |
| Oct 15, 2026 | 11.90M | 10.53% | -8% | 2.12M | 5.6 |
| Sep 30, 2026 | 12.91M | 11.42% | -8% | 2.36M | 5.5 |
| Sep 15, 2026 | 14.07M | 12.44% | -9% | 2.42M | 5.8 |
| Aug 31, 2026 | 15.47M | 13.68% | -2% | 2.65M | 5.8 |
| Aug 14, 2026 | 15.77M | 13.95% | -0% | 3.99M | 4.0 |
| Jul 31, 2026 | 15.81M | 14.06% | +8% | 4.36M | 3.6 |
| Jul 15, 2026 | 14.69M | 13.06% | -7% | 2.22M | 6.6 |
| Jun 30, 2026 | 15.83M | 14.07% | +9% | 2.68M | 5.9 |
| Jun 15, 2026 | 14.58M | 12.97% | -1% | 2.57M | 5.7 |
| May 29, 2026 | 14.79M | 13.15% | -1% | 2.33M | 6.4 |
| May 15, 2026 | 14.94M | 13.29% | -3% | 3.01M | 5.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Evolent Health company events
Evolent Health filed 7 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 4, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Feb 24, 2026ResultsReleased financial results. Filing
- Dec 8, 2025AnnouncementEvolent Health LLC, a wholly owned subsidiary of Evolent Health, Inc., consummated the transactions contemplated by the previously announced Stock Purchase Agreement, dated September 23, 2025, by and between Evolent Health LLC and Privia Management Company, LLC. SIGNATURES Pursuant to the… Filing
- Dec 2, 2025LeadershipMs. Cheryl Scott retired from the Board of Directors of Evolent Health, Inc. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Evolent Health financials
Famous investors that hold EVH
3 of the 50 well-known investors we track reported holding EVH in their latest 13F filing. The largest position is Israel Englander's, worth $2.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 680,397 | $2.4M | 0.0% | +124% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 624,328 | $2.2M | 0.0% | +28% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 566,905 | $2M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named EVH in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Cadian Capital Management, LP | 13G/A | 0.5% |
| Nov 16, 2026 | Cadian Capital Management, LP | 13G/A | 0.5% |
| Nov 13, 2026 | Rubicon Fund II LP | 13G/A | 4.4% |
| Nov 13, 2026 | Rubicon Fund II LP | 13G/A | 4.4% |
Questions about Evolent Health, Inc. (EVH) stock
Who owns the most EVH stock?
The largest reported owner of Evolent Health, Inc. (EVH) is BlackRock, Inc., with 13.2% of the company. In total, 199 funds and institutions reported holding EVH at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are EVH insiders buying or selling?
In the last 12 months, EVH insiders reported 1 open-market purchase worth $38.2K and 1 sale worth $329K. The latest trade was on Aug 26, 2026. See every trade.
What is the short interest in EVH?
As of Oct 30, 2026, 10.61M EVH shares were sold short, 9.4% of the shares outstanding, down 10.9% from the report before. At the average daily volume of 1.52M shares, buying them all back would take about 7.0 trading days (days to cover). See the history.
Which famous investors hold EVH?
3 of the 50 well-known investors we track reported EVH in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $2.4M. See all holders.
Executive pay
Evolent Health's chief executive was paid a total of $14.2M for the year ended Dec 31, 2025, up 28% from $11.1M the year before. In the last 12 months, Evolent Health's executives and directors bought $38.2K of stock on the open market and sold $329K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.